Preferred Label : GSK-3 Inhibitor LY2090314;
NCIt synonyms : 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione;
NCIt related terms : LY-2090314;
NCIt definition : An inhibitor of glycogen synthase kinase-3 (GSK-3), with potential antineoplastic
activity. Upon administration, LY2090314 binds to and inhibits GSK-3 in an ATP-competitive
manner. This prevents GSK-3-mediated phosphorylation of beta-catenin, which inhibits
the subsequent ubiquitination and proteasomal degradation of beta-catenin. This leads
to the activation of the Wnt/beta-catenin pathway and the induction of apoptosis in
susceptible tumor cells. GSK-3, a serine/threonine kinase, plays a key role in numerous
pathways involved in protein synthesis, cellular proliferation, differentiation, and
apoptosis. The Wnt/beta-catenin signaling pathway plays key roles in both cellular
proliferation and differentiation. The increased expression of beta-catenin, a transcriptional
activator, correlates with decreased cellular proliferation and improved prognosis
in select cancers.;
UNII : 822M3GYM67;
CAS number : 603288-22-8;
Molecule name : LY-2090314; LY 2090314;
Origin ID : C116849;
UMLS CUI : C3713994;
Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
- has_target
